10x Genomics TXG
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
10x Genomics (TXG) Core Market Data and Business Metrics
Latest Closing Price
$8.85Price-Earnings Ratio
-5.82Total Outstanding Shares
108.25 Million SharesDividend
No dividendSIC Description
Laboratory Analytical InstrumentsPrimary Exchange
NASDAQHeadquarters
6230 Stoneridge Mall Road, Pleasanton, CA, 94588
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 3,419,638 Shares | 3.53 | 3/14/2025 | 12,075,180 Shares |
| 2,996,643 Shares | 4.59 | 2/28/2025 | 13,768,808 Shares |
| 3,563,627 Shares | 3.18 | 2/14/2025 | 11,315,858 Shares |
| 1,917,295 Shares | 4.39 | 1/31/2025 | 8,423,614 Shares |
| 1,947,646 Shares | 3.91 | 1/15/2025 | 7,605,935 Shares |
| 1,605,314 Shares | 4.11 | 12/31/2024 | 6,600,347 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $10.91 Million |
| Exchange Gains/Losses | $-164,000 |
| Net Cash Flow From Financing Activities, Continuing | $10.91 Million |
| Net Cash Flow From Investing Activities, Continuing | $-32.63 Million |
| Net Cash Flow From Investing Activities | $-32.63 Million |
| Net Cash Flow, Continuing | $-15.05 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Current | $4.22 Million |
| Gross Profit | $414.48 Million |
| Operating Expenses | $609.04 Million |
| Income/Loss From Continuing Operations After Tax | $-182.63 Million |
| Basic Average Shares | $120.45 Million |
| Income/Loss From Continuing Operations Before Tax | $-177.70 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-182.69 Million |
| Other Comprehensive Income/Loss | $-182.69 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-182.69 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-64,000 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $918.64 Million |
| Noncurrent Liabilities | $90.87 Million |
| Other Non-current Assets | $65.93 Million |
| Wages | $33.62 Million |
| Noncurrent Assets | $334.25 Million |
| Liabilities | $208.50 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||